In one of the Biden administration’s final health policy pushes, the White House unveiled a proposal to ensure Medicare and ...

Here are six recent GLP-1 studies: 1. The use of Ozempic and Wegovy reduced healthcare costs for overweight or obese patients with heart failure or atherosclerotic cardiovascular disease, according to ...

Related: Crazy-expensive weight loss drugs may soon see a major change In other news, The Biden Administration is set to ...

CMS proposes changes to Medicare and Medicaid to cover weight-loss drugs, recognizing obesity as a disease. This could expand ...

TennCare is federally required to cover GLP-1 drugs; of the $118M in the cost increase request, more than $76 million would ...

Currently, fewer than one in five large employers are covering such prescriptions despite the boom in popularity of expensive GLP-1 drugs to treat weight loss, according to a KFF analysis earlier this ...

President Joe Biden’s proposal to have GLP-1 weight-loss drugs such as Ozempic and Mounjaro covered by Medicare and Medicaid ...

A study of 14,000 WeightWatchers participants is the latest to suggest that Ozempic and similar obesity drugs could be ...

U.S. President Joe Biden on Tuesday proposed expanding coverage of anti-obesity drugs, like Novo Nordisk's Wegovy, for more ...

The Biden administration wants to expand coverage of anti-obesity medications to millions on Medicare, Medicaid.

The thyroid medication levothyroxine may be associated with bone loss, according to a study that will be presented at the ...

Whether this proposed rule actually has any impact remains to be seen, especially with a new administration led by Donald ...